UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2015
Intelgenx Technologies Corp. 
 (Exact name of registrant as specified in its charter)

Delaware	000-31187	87-0638336	
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer ID)	
6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada
 (Address of principal executive offices and Zip Code)
(514) 331-7440
 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 	
|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 	
|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 	
|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 1.02. Termination of a Material Definitive Agreement.
On May 12, 2015, the Board of Directors of IntelGenx Technologies Corp. (“the Company”) accepted the resignation of Paul A. Simmons as Chief Financial Officer of the “Company”. Mr. Simmons resignation results in the termination of the Employment Agreement (the “Agreement”) between IntelGenx Corp, the Company’s wholly owned subsidiary, and Mr. Simmons dated July 18, 2008 and filed with the United States Securities and Exchange Commission as Exhibit 10.6 to our Form 8-K dated September 05, 2008.
Item 5.02. Departure of Certain Officers; Appointment of Certain Officers.
Mr. Simmons resigned as the Chief Financial Officer, effective May 22, 2015. The Company’s Board of Directors accepted Mr. Simmons’s resignation. Mr. Simmons’s resignation is not the result of any disputes, claims or issues with the Company.
The Company has initiated a search process for the selection and appointment of a new Chief Financial Officer.
Item 8.01 Other Events .
On May 13, 2015, the Company issued a press release announcing the resignation. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit	Description	
99.1	Press Release dated May 13, 2015	
INTELGENX TECHNOLOGIES CORP.

Dated: May 13, 2015	By: /s/ Horst Zerbe                                               	
 	      Horst G. Zerbe	
 	      Chairman of the Board	

Exhibit 99.1
IntelGenx Announces Management Changes
SAINT LAURENT, QUEBEC , May 13, 2015 - IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”) announced today that Mr. Paul Simmons has resigned as Chief Financial Officer (“CFO”) of IntelGenx and IntelGenx Corp, effective May 22, 2015.
The Company has begun a search process for the selection and appointment of a new Chief Financial Officer.
The Board thanks Mr. Simmons for his service and contributions to the company and wishes him well in his future endeavours.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com .
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2014, filed with the United States Securities and Exchange Commission and available at www.sec.gov , and also filed with Canadian securities regulatory authorities and www.sedar.com . IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.
CONTACT:
Dr. Horst G. Zerbe,
President and CEO
horst@IntelGenx.com
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com